FREE DM Review Site Registration!
Sign-up today and access DM Review on the Web!

Your FREE registration entitles you to:
FREE email newsletters

FREE access to all DM Review content

FREE access to web seminars, resource portals, our white paper library and more!

   

FDA Selects Appian BPM for Process-based Applications

October 27, 2008 - The U.S. Food and Drug Administration (FDA) selected Appian Enterprise BPM Suite as its platform of choice for the development of process-centric applications.

 

The FDA, the scientific regulatory agency responsible for protecting and advancing the public health in the U.S., chose Appian’s comprehensive BPM Suite in support of a strategic vision to transform FDA operations in response to emerging scientific, technological and economic trends affecting its regulatory mission.

 

Using BPM technology, the FDA expects to provide more accurate and timely data with which to make decisions that directly affect its core duties. Additionally, the time and money saved using Appian will allow a greater opportunity to enhance services to the various FDA centers.

 

The U.S. Food and Drug Administration’s more than 10,000 scientific, technical and support staff affect the lives of every American every day. Consumers spend nearly $1.5 trillion each year on FDA-regulated products, which represents over 20 percent of all consumer expenditures. The FDA believes that developing a process-centric approach to IT development will provide improved support in advancing the public health by helping to speed innovations that make medicines and foods more effective, safer and more affordable; and helping the public get the accurate, science-based information they need to use medicines and foods to improve their health.

 

By providing standard reference architecture, development practices, tools and examples through reference implementation, the FDA will be able to transform its IT practices into a holistic approach that better-serves the enterprise and the public.

 

“BPM is fundamentally changing the way government agencies operate,” said Matthew Calkins, president and CEO of Appian. “Viewing application development as an agency-wide effort instead of each individual center managing their own practices will improve the coordination and orchestration of how IT supports the FDA’s mission.”


This piece is brought to you by the DM Review editorial staff.

For more information on related topics, visit the following channels:



Industry Vendors